tag:blogger.com,1999:blog-54380708923168538362024-02-20T03:51:50.361-08:00Cutaneous LymphomaA lymphatic cancer involving the skin. This will be a clearinghouse of information, abstracts, studies and support. I am a thirteen year survivor of Cuatneous B Cell lymphoma and 56 year survivor of hereditary lymphedema.Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.comBlogger69125tag:blogger.com,1999:blog-5438070892316853836.post-48317766754464201382013-03-03T06:30:00.001-08:002013-03-03T06:30:17.632-08:00Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.<br />
<h1 style="background-color: white; border: 0px; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;">Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in <span class="highlight" style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>.</span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>2013 Mar </b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Biskup%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23445313" style="border: 0px; color: #660066; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Biskup E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kamstrup%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=23445313" style="border: 0px; color: #660066; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kamstrup MR</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Manf%C3%A9%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23445313" style="border: 0px; color: #660066; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Manfé V</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Gniadecki%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23445313" style="border: 0px; color: #660066; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Gniadecki R</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font-style: inherit; font-variant: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;">Source</span></h3>
<div style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, Copenhagen-2400, Denmark.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; display: inline; font-style: inherit; font-variant: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;">Abstract</span></h3>
</div>
<div class="abstr" style="background-color: white; border: 0px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<div class="" style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<div style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #b45f06; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Background </b></span></div>
<div style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>We have previously discovered that Notch1 is expressed on malignant T cells in <span class="highlight" style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>(CTCL), and is required for survival of CTCL cell lines. Notch can be inhibited by γ-secretase inhibitors (GSIs), which differ widely in their ability to induce apoptosis in CTCL. Objectives To investigate whether GSI-I, in addition to inhibiting Notch, induces apoptosis in CTCL by proteasome inhibition, as GSI-I is very potent and has structural similarity to the proteasome inhibitor MG-132. Methods Cell lines derived from CTCL (MyLa, SeAx, JK, Mac1 and Mac2a) were treated with GSI-I and two other proteasome inhibitors (MG-132 and bortezomib). The effects on cell viability, apoptosis and proteasome activity were measured, as was the impact on the prosurvival, nuclear factor κB (NF-κB) pathway. Results In CTCL, GSI-I had proteasome-blocking activity with a potency comparable to the proteasome inhibitors MG-132 and bortezomib. </b></span></div>
<div style="border: 0px; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Proteasome inhibition was the main mechanism responsible for GSI-I-induced cell death, as tiron, a compound known to reverse the effect of MG-132, restored proteasome activity and largely abrogated the cytotoxic effect of GSI-I. Although inactivation of NF-κB is an important mechanism of action for proteasome inhibitors, we demonstrated an apparent activation of NF-κB. Furthermore, we showed that while the tumour suppressor protein p53 was induced during proteasome inhibition, it was dispensable for CTCL apoptosis, as both SeAx cells, which harbour p53 mutations that attenuate the apoptotic capacity, and HuT-78 cells, which have a deleted p53 gene, demonstrated potent apoptotic response. Conclusions GSI-I represents an interesting drug with a dual mechanism of action comprising inhibition of both Notch and the proteasome.</b></span></div>
<div style="border: 0px; font-family: inherit; font-size: inherit; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font-family: inherit; font-size: inherit; font-style: inherit; font-variant: inherit; line-height: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23445313">PubMed</a></div>
</div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com3tag:blogger.com,1999:blog-5438070892316853836.post-17146273146815549402013-02-17T08:43:00.004-08:002013-02-17T08:43:57.672-08:00Array-CGH Analysis of Cutaneous Anaplastic Large Cell Lymphoma.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Array-CGH Analysis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> Anaplastic Large Cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lymphoma</span>.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Szuhai%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23412792" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Szuhai K</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Doorn%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23412792" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">van Doorn R</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tensen%20CP%5BAuthor%5D&cauthor=true&cauthor_uid=23412792" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Tensen CP</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Van%20Kester%5BAuthor%5D&cauthor=true&cauthor_uid=23412792" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Van Kester</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; display: inline; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<div class="" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>This chapter describes a study in which the pattern of numerical chromosomal alterations in <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> anaplastic large cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (C-ALCL) tumor samples was defined using array-based comparative genomic hybridization (CGH). First, the array-based CGH technique applied is outlined in detail. Next, its application in the analysis of C-ALCL tumor specimens is described. This approach resulted in the identification of highly recurrent chromosomal alterations in C-ALCL that include gain of 7q31 and loss on 6q16-6q21 and 13q34, each affecting 45% of the patients. The pattern characteristic of C-ALCL differs markedly from chromosomal alterations observed in other CTCL such as mycosis fungoides and Sézary syndrome and yielded several candidate genes with potential relevance in the pathogenesis of C-ALCL.</b></span></div>
<div style="border: 0px; font-size: 15.600000381469727px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font-size: 15.600000381469727px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23412792">PubMed</a></div>
</div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1tag:blogger.com,1999:blog-5438070892316853836.post-4265323806165974552013-02-08T08:25:00.001-08:002013-02-08T08:25:18.813-08:00Indolent course of cutaneous gamma-delta T-cell lymphoma.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Indolent course of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> gamma-delta T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #660000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Feb 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Endly%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=23379625" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Endly DC</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Weenig%20RH%5BAuthor%5D&cauthor=true&cauthor_uid=23379625" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Weenig RH</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Peters%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=23379625" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Peters MS</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Viswanatha%20DS%5BAuthor%5D&cauthor=true&cauthor_uid=23379625" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Viswanatha DS</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Comfere%20NI%5BAuthor%5D&cauthor=true&cauthor_uid=23379625" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Comfere NI</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #783f04; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; display: inline; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<div class="" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #783f04; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> gamma-delta T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> is a rare malignancy that typically displays an aggressive clinical course. We present an unusual case of a 57-year-old woman with a 3-year history of lower extremity nodules. Histopathologic, immunophenotypic and molecular genetic studies revealed a clonal, predominantly pannicular gamma-delta T-cell infiltrate, leading to a diagnosis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphoma. The clinical course was characterized by rapid improvement within months of starting systemic corticosteroids, with relapse in ulcerations but no new lesions more than 3 years after onset of disease. Our case and seven previously reported patients with indolent and relatively localized <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphoma provide evidence that not all cases of this entity carry a poor prognosis. This indolent subset adds complexity to treatment of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphoma.</b></span></div>
<div style="border: 0px; font-size: 15.600000381469727px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font-size: 15.600000381469727px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://onlinelibrary.wiley.com/doi/10.1111/cup.12091/abstract;jsessionid=9AF42DFB8415F0D4895161F527A9F714.d02t04">Wiley Online</a></div>
</div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1tag:blogger.com,1999:blog-5438070892316853836.post-89822607803053277062013-02-01T08:09:00.005-08:002013-02-01T08:09:48.824-08:00The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis incutaneous T-cell lymphoma cell lines.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> cell lines.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Feb 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=D%C3%B6bbeling%20U%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Döbbeling U</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Waeckerle-Men%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Waeckerle-Men Y</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Zabel%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Zabel F</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Graf%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Graf N</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=K%C3%BCndig%20TM%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kündig TM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Johansen%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23362870" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Johansen P</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Mycosis fungoides and its leukaemic counterpart Sézary syndrome are the most frequent <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell lymphomas (CTCL), and there is no cure for these diseases. We evaluated the effect of clinically approved antihistamines on the growth of CTCL cell lines. CTCL cell lines as well as blood lymphocytes from patients with Sézary syndrome were cultured with antihistamines, and the cell were analysed for proliferation, apoptosis and expression of programmed death molecules and transcription factors. The two antihistamines clemastine and desloratadine, currently used for symptom alleviation in allergy, induced potent reduction of the activities of the constitutively active transcription factors c-Myc, STAT3, STAT5a and STAT5b in mycosis fungoides and Sézary syndrome cell lines. This inhibition was followed by apoptosis and cell death, especially in the Sézary syndrome-derived cell line Hut78 that also showed increased expression of the programmed death-1 (PD-1) after clemastine treatment. In lymphocytes isolated from Sézary syndrome patients, the CD4-positive fraction underwent apoptosis after clemastine treatment, while CD4-negative lymphocytes were little affected. Because both c-Myc and STAT transcription factors are highly expressed in proliferating tumours, their inhibition by clemastine, desloratadine and other inhibitors could complement established chemotherapies not only for <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell lymphomas but perhaps also other cancers.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23362870">PubMed</a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1tag:blogger.com,1999:blog-5438070892316853836.post-35516724389768635892013-02-01T08:07:00.003-08:002013-02-01T08:07:24.417-08:00TCR-γ Expression in Primary Cutaneous T-cell Lymphomas.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>TCR-γ Expression in Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> T-cell Lymphomas.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Jan 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Rodr%C3%ADguez-Pinilla%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Rodríguez-Pinilla SM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Ortiz-Romero%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Ortiz-Romero PL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Monsalvez%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Monsalvez V</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tom%C3%A1s%20IE%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Tomás IE</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Almagro%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Almagro M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Sevilla%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Sevilla A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Camacho%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Camacho G</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Longo%20MI%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Longo MI</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pulpillo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Pulpillo A</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Diaz-P%C3%A9rez%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Diaz-Pérez JA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Montes-Moreno%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Montes-Moreno S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Castro%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Castro Y</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Echevarr%C3%ADa%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Echevarría B</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tr%C3%A9bol%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Trébol I</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Gonzalez%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Gonzalez C</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=S%C3%A1nchez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Sánchez L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Ot%C3%ADn%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Otín AP</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Requena%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Requena L</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Rodr%C3%ADguez-Peralto%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Rodríguez-Peralto JL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cerroni%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cerroni L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Piris%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=23348211" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Piris MA</a>.</b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>*CNIO <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lymphoma</span> Group Departments of †Pathology ‡‡‡Dermatology, Fundación Jiménez Díaz Departments of ‡Dermatology §§§Pathology, Hospital Universitario 12 de Octubre §Pathology Department, Hospital de Torrejón de Ardoz Departments of **Dermatology ∥∥Pathology, Hospital Universitario Gregorio Marañón ***Dermatology Department, Hospital Universitario de Getafe, Getafe †††Immunohistochemistry Unit, Biotechnology Programme, CNIO, Madrid ∥Dermatology Department, Hospital Universitario Juan Canalejo, La Coruña ¶Dermatology Department, Hospital de San Juan, Alicante #Dermatology Department, Hospital Universitario Reina Sofía, Córdoba ††Dermatology Department, Hospital Universitario Virgen del Rocío, Sevilla §§Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander ¶¶Dermatology Department, Hospital Virgen del Castillo, Murcia ##Dermatology Department, Hospital Santiago Apostol, Vitoria, Spain ‡‡UCSD Moores Cancer Center, La Joya, CA ∥∥∥Department of Dermatology, Research Unit Dermatopathology, Medical University of Graz, Graz, Austria.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> γδ T-cell lymphomas (PCGD-TCLs) are considered a subgroup of aggressive cytotoxic T-cell lymphomas (CTCLs). We have taken advantage of a new, commercially available antibody that recognizes the T-cell receptor-γ (TCR-γ) subunit of the TCR in paraffin-embedded tissue. We have analyzed a series of 146 primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell lymphomas received for consultation or a second opinion in the CNIO Pathology Department. Cases were classified according to the World Health Organization 2008 classification as mycosis fungoides (MF; n=96), PCGD-TCLs (n=5), pagetoid reticulosis (n=6), CD30 primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> anaplastic large cell lymphomas (n=5), primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD8 aggressive epidermotropic CTCLs (n=3), primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CTCL, not otherwise specified (n=4), and extranodal nasal-type NK/T-cell lymphomas primarily affecting the skin or subcutaneous tissue (n=11). Sixteen cases of the newly named lymphomatoid papulosis type D (LyP-D; n=16) were also included. In those cases positive for TCR-γ, a further panel of 13 antibodies was used for analysis, including TIA-1, granzyme B, and perforin. Clinical and follow-up data were recorded in all cases. Twelve cases (8.2%) were positive for TCR-γ, including 5 PCGD-TCLs, 2 MFs, and 5 LyP-Ds. All 5 PCGD-TCL patients and 1 MF patient died of the disease, whereas the other MF patient and all those with LyP-D were alive. All cases expressed cytotoxic markers, were frequently CD3/CD8, and tended to lose CD5 and CD7 expressions. Eight of 12 and 5 of 11 cases were CD30 and CD56, respectively. Interestingly, 5/12 TCR-γ-positive cases also expressed TCR-BF1. All cases analyzed were negative for Epstein-Barr virus-encoded RNA. In conclusion, TCR-γ expression seems to be rare and is confined to cytotoxic primary<span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> TCLs. Nevertheless, its expression is not exclusive to PCGD-TCLs, as TCR-γ protein can be found in other CTCLs. Moreover, its expression does not seem to be associated with bad prognosis by itself, as it can be found in cases with good and bad outcomes.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://journals.lww.com/ajsp/pages/articleviewer.aspx?year=9000&issue=00000&article=98890&type=abstract">American Journal of Surgical Pathology</a></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1tag:blogger.com,1999:blog-5438070892316853836.post-36491779144519951432013-01-30T07:58:00.001-08:002013-01-30T07:58:58.383-08:00Positron Emission Tomography Revealed Diffuse Involvement of the Lower Legs and Occult Extracutaneous Lesions in Subcutaneous Panniculitis-Like T-cell Lymphoma.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="color: orange;">Positron Emission Tomography Revealed Diffuse Involvement of the Lower Legs and Occult Extracutaneous Lesions in Subcutaneous Panniculitis-Like T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lymphoma</span>.</span></b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="color: #990000;">Jan 2013 </span><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mitsuhashi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23354029" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Mitsuhashi K</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Momose%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23354029" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Momose M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Masuda%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23354029" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Masuda A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Tsunemi%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23354029" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Tsunemi Y</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Motoji%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23354029" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Motoji T</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>From the *Department of Hematology, †Department of Diagnostic Imaging and Nuclear Medicine, ‡Department of Surgical Pathology, and §Department of Dermatology, Tokyo Women's Medical University, Tokyo, Japan.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #ea9999; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>ABSTRACT: </b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="color: #990000;">Subcutaneous panniculitis-like</span> <a href="http://www.lymphedemapeople.com/wiki/doku.php?id=glossary:t_cell">T-cell</a> <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><a href="http://www.lymphedemapeople.com/wiki/doku.php?id=glossary:lymphoma">lymphoma</a></span> <span style="color: #990000;">(SPTCL) is a very rare type of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> that localizes primarily in the subcutaneous <a href="http://www.lymphedemapeople.com/wiki/doku.php?id=glossary:adipose_tissue">adipose tissue</a> without palpable involvement of the <a href="http://www.lymphedemapeople.com/wiki/doku.php?id=lymph_nodes">lymph nodes</a>. Most often, it presents as multiple, painless, subcutaneous nodules on the extremities and trunk. In this study, we describe an unusual case of SPTCL that mimicked phlegmonous inflammation; PET/<a href="http://www.lymphedemapeople.com/wiki/doku.php?id=glossary:ct_scan">CT</a> revealed massive diffuse involvement of the lower legs, low-grade nodal active disease, and occult involvement of the intra-abdominal visceral fat. A repeat PET/CT study after CHOP chemotherapy revealed complete resolution of abnormal FDG uptake in the initially involved sites.</span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="color: #990000;"><br /></span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="color: #990000;"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23354029">PubMed</a></span></span></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-48187040363537014342013-01-21T08:26:00.001-08:002013-01-21T08:26:12.861-08:00Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Composite <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of mycosis fungoides and <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> small B-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> in a 73-year-old male patient.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Jan 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Whitling%20NA%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Whitling NA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Shanesmith%20RP%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Shanesmith RP</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Jacob%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Jacob L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=McBurney%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">McBurney E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Sebastian%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Sebastian S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Wang E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=23313307" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Wang AR</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Pathology, Tulane University, New Orleans, LA, USA 70112.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Composite <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of T-cell and B-cell type is uncommon, and the one occurring primarily on skin is extremely rare. Herein, we report a unique case of composite <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of mycosis fungoides and <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> small B-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> in a 73-year-old male patient. The patient presented with multiple erythematous patches, plaques, and nodules on the upper arms, scalp, and trunk. Four punch biopsies of arm and scalp lesions demonstrated lymphoid infiltrate in superficial to deep dermis with a characteristic zone distribution of T-cell and B-cell components. T cells were distributed in papillary and perifollicular dermis and displayed a larger size with convoluted nuclei, whereas B cells were small sized, assuming nodular infiltrate in mid-deep dermis with coexpression of CD5. Molecular test detected clonal rearrangement of both TCRG and IGH/K genes with identical amplicons for each gene in all 4 biopsies. Clinical staging revealed no extracutaneous lesions. A multidisplinary approach is emphasized to establish a definitive diagnosis.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.humanpathol.com/article/S0046-8177(12)00355-3/abstract">PubMed</a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com4tag:blogger.com,1999:blog-5438070892316853836.post-20802182417474701752013-01-13T07:59:00.004-08:002013-01-13T07:59:38.098-08:00New Insights into Associated Co-morbidities in Patients with Cutaneous T-cell Lymphoma (Mycosis Fungoides).<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>New Insights into Associated Co-morbidities in Patients with <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lymphoma</span> (Mycosis Fungoides).</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Jan 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hodak%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Hodak E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lessin%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lessin S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Friedland%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Friedland R</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Freud%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Freud T</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=David%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">David M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pavlovsky%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Pavlovsky L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Shapiro%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Shapiro J</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cohen%20AD%5BAuthor%5D&cauthor=true&cauthor_uid=23303582" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cohen AD</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, Rabin Medical Center, Petah Tiqva, 49100, Peath Tiqva, Israel. hodake@post.tau.ac.il.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Studies of associated cancer in patients with mycosis fungoides (MF) have focused primarily on secondary cancers in North American and European populations. This study investigated the association between MF and malignancies, anxiety and depression in the Israeli population. Data on Israeli patients with MF and age- and gender-matched controls were collected from a database of population- based cohort (683 patients; 1,700 controls) and an institution- based cohort (343 patients; 846 controls) and analysed by univariate and multivariate methods. MF was significantly associated with Hodgkin's <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> in both cohorts (multivariate odds ratio (OR) 7.83, univariate OR ∞, respectively); acute leukaemia (multivariate OR 10.1, first cohort) and lung cancer (multivariate OR 10.15, second cohort). MF was significantly associated with anxiety and depression (multivariate OR 1.59, OR 1.51, respectively in first cohort). The current study provides support to the associations between MF and other cancers: Hodgkin's <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>, acute leukaemia and lung cancer. The study also em-phasizes the association between MF and anxiety and depression.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-size: 15.600000381469727px;"><br /></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-size: 15.600000381469727px;"><a href="http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1496">Medical Journals</a></span></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-84458765620212580512013-01-13T07:54:00.001-08:002013-01-13T07:56:51.587-08:00Serum-soluble Herpes Virus Entry Mediator Levels Reflect Disease Severity and Th2 Environment in Cutaneous T-cell Lymphoma<b style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: x-large;">Serum-soluble Herpes Virus Entry Mediator Levels Reflect Disease Severity and Th2 Environment in Cutaneous T-cell Lymphoma</b><br />
<span style="font-size: large;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif;"><b><br /></b></span>
</span><br />
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Tomomitsu Miyagaki, Makoto Sugaya*, Hiraku Suga, Hanako Ohmatsu, Hideki Fujita, Yoshihide Asano, Yayoi Tada, Takafumi</b></span><br />
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Kadono and Shinichi Sato</b></span><br />
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. *E-mail: sugayam-der@h.u-tokyo.ac.jp</b></span><br />
<span style="font-size: large;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif;"><b><br /></b></span>
<b style="color: #990000; font-family: Arial, Helvetica, sans-serif;">Activated T cells express LIGHT, an acronyme for lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for herpesvirus entry mediator (HVEM) a receptor expressed by T lymphocytes (1). LIGHT binds to 3 distinct receptors: HVEM, lymphotoxin β receptor, and decoy receptor 3 (2). Of these, HVEM is expressed by many cell types (1). LIGHT-HVEM interactions activate T cells and natural killer (NK) cells to produce T helper type (Th) 1 cytokines (3–7).</b></span><br />
<br />
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Many patients with cutaneous T-cell lymphoma (CTCL) in the advanced stages have eosinophilia and high levels of immunoglobulin E, suggesting that Th2 is dominant in these patients (8, 9).</b></span><br />
<span style="font-size: large;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif;"><b><br /></b></span>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif;"><b>We reported recently that low HVEM expression on dermal fibroblasts in lesional skin of advanced CTCL attenuates the expression of Th1 chemokines, which may contribute to a shift to a Th2-dominant microenvironment (10). However, little is known about the soluble</b></span></span><br />
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>form of HVEM (sHVEM) and its ligand, LIGHT, in CTCL. The aim of this study was to measure sHVEM and LIGHT levels in the sera of patients with CTCL.</b></span><br />
<br />
<span style="color: #e69138;"><b>working link not available</b></span><br />
<span style="color: #e69138;"><b><br /></b></span>
<span style="color: #e69138;"><b>Medical Journals</b></span><br />
<span style="background-color: white; color: #009933; font-family: arial, sans-serif; font-size: x-small; line-height: 12px;"><br /></span>
<span style="background-color: white; color: #009933; font-family: arial, sans-serif; font-size: x-small; line-height: 12px;"><br /></span>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-18929909447524804152013-01-06T08:50:00.000-08:002013-01-06T08:50:05.213-08:00Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin - Consensus of thelymphoma group of the Working Group Dermatologic Oncology.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Treatment of advanced <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell lymphomas with non-pegylated liposomal doxorubicin - Consensus of the <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> group of the Working Group Dermatologic Oncology.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Jan 2013</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Assaf%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Assaf C</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Becker%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Becker JC</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Beyer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Beyer M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cozzio%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cozzio A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Dippel%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Dippel E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Klemke%20CD%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Klemke CD</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kurschat%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kurschat P</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Weichenthal%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Weichenthal M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Stadler%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23279629" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Stadler R</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatlogy, Helios Clinic Krefeld, Germany Department of Dermatology and Venereology, University of Graz, Austria Department of Dermatolgogy, Venereology and Allergology, Charité- University Medicine Berlin, Germany Department of Dermatology, University Clinic Zurich, Switzerland Department of Dermatolgoy, Municipal Clinic Ludwigshaven, Germany Department of Dermatology, University of Mannheim, Germany Department of Dermatology and Venereology, University of Cologne, Germany Department of Dermatology, University of Kiel, Germany Department of Dermatolgy, Johannes Wesling Clinic Minden, Germany.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="color: #ea9999;"><i>Background:</i></span> <span style="color: #990000;">Systemic treatment with pegylated liposomal doxorubicin is an established second-line treatment of advanced<span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>. Pegylated liposomal doxorubicin (PLD) is currently unavailable, therefore, clinical studies investigating the efficacy of non-pegylated liposomal formula (NPLD) have been analyzed. </span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><i><span style="color: #ea9999;">Methods:</span></i> <span style="color: #990000;">Since clinical trials comparing PLD and NPLD in CTCL do not exist, the clinical use of NPLD including safety and efficiency profile in other types of non-Hodgkin <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> were analyzed. </span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><i><span style="color: #ea9999;">Results: </span></i><span style="color: #990000;">Clinical trials show a comparable efficacy of NPLD and PLD in non-Hodgkin <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>. The dosage of NPLD used in the treatment of systemic <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> within polychemotherapy regimens was 50 mg/m(2) every three weeks. Overall response was 75-95 %, including a complete remission rate of 65-80 % and 2- and 3-year overall survival rates of 55-75 %. These data indicate that the non-pegylated formula of doxorubicin has a similar antitumor effect as the pegylated one but shows reduced cardiotoxicity. The palmoplantar erythrodysesthesia frequently observed in PLD has not been observed with the use of the NPLD. </span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><i><span style="color: #ea9999;">Conclusions: </span></i><span style="color: #990000;">The clinical use of NPLD in the treatment of CTCL is reasonable. In analogy to the clinical trials of NPLD in non-Hodgkin <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> a dosage of 50 mg/m(2) every three weeks is recommended for the treatment of CTCL.</span></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://onlinelibrary.wiley.com/doi/10.1111/ddg.12012/abstract;jsessionid=1D2E93C603A1E246ACECCF65FA3A4EED.d04t01">Wiley Online</a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-31908809526488275062013-01-06T08:46:00.000-08:002013-01-06T08:46:07.037-08:00Primary cutaneous CD30-positive anaplastic large-cell lymphoma of the external auditory canal.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD30-positive anaplastic large-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of the external auditory canal.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mar%C3%A7al%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Marçal N</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Campelos%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Campelos S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Dias%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Dias L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Gon%C3%A7alves%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Gonçalves M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pereira%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Pereira G</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Godinho%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23288823" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Godinho T</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Otorhinolaryngology, Hospital de São Marcos, Sete Fontes, S. Victor 4701-243 Braga, Portugal. nunomarcal.orl@gmail.com.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> is rare. <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> is defined as primary when there is an absence of nodal or systemic disease during the first 6 months following diagnosis. We report what we believe to be the first documented case of a primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD30-positive anaplastic large-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of the external auditory canal. The patient was an elderly woman who presented with progressively worsening right otalgia and hypoacusis. Otoscopy revealed an erythematic, ulcerative, nonbleeding, localized lesion in the anterosuperior area of the external auditory canal. The patient underwent an excisional biopsy, and after the diagnosis was established, she underwent 22 sessions of radiotherapy. During follow-up, she exhibited no evidence of recurrence.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23288823">PubMed</a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-1356324466008967612013-01-01T07:43:00.000-08:002013-01-01T07:43:01.714-08:00Dermatopathology Update.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dermatopathology Update.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="lang" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>[Article in English, Spanish]</b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Fern%C3%A1ndez-Figueras%20MT%5BAuthor%5D&cauthor=true&cauthor_uid=23273924" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Fernández-Figueras MT</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Puig%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23273924" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Puig L</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Servicio de Anatomía Patológica, Hospital Universitari Germans Trias i Pujol, Badalona, España; Departamento de Ciencias Morfológicas, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: maiteffig@gmail.com.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>This past year has seen a wealth of new developments in dermatopathology that appear to herald the dawning of a new era. Advances in molecular biology and the simplification of techniques have put molecular tests within reach of routine clinical practice and led to a radical change in our approach to lesions such as melanoma; in the future, the genetic characterization of these lesions will be an essential requirement for establishing diagnosis, prognosis, and therapy. </b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Technological innovations have also reached dermatology departments: the introduction of ultrasound scans has propitiated the use of fine-needle aspiration cytology, which allows samples to be stained and studied immediately, thereby facilitating diagnosis of superficial and lymph-node lesions, and allowing staging of tumors such as melanoma. Targeted cancer therapies have led to the introduction of more sensitive and specific systems for identifying new targets, have reawakened interest in forgotten diseases such as aggressive basal cell carcinoma, and have led to dermatological reactions that, together with those caused by biologic drugs, we are just beginning to recognize. Consolidated techniques such as immunohistochemistry continue to advance with the addition of new antibodies that contribute considerably to improved diagnosis.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>New clinicopathologic diseases have also been described or characterized this year, including 2 new types of melanoma, and progress has been made in our knowledge of other diseases, such as primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD4(+) small/medium-sized pleomorphic T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>. These topics, together with new developments in adnexal tumors, alopecia, and other lesions, will be discussed in this review.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><br /></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23273924"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;">PubMed</span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-89442149981416714042012-12-26T07:10:00.001-08:002012-12-26T07:10:24.646-08:00Proteome-Based Analysis of Serologically Defined Tumor-Associated Antigens in Cutaneous Lymphoma<br />
<h1 class="content-title" style="background-color: white; border: 0px; font: inherit; line-height: 1.5; margin: 1em 0px 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Proteome-Based Analysis of Serologically Defined Tumor-Associated Antigens in Cutaneous Lymphoma</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Just released through PLOS </b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>December 2009</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Forgber%20M%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Michael Forgber</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"></sup><span style="background-color: white; line-height: 20.399999618530273px;"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Gellrich%20S%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Sylke Gellrich</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"></sup><span style="background-color: white; line-height: 20.399999618530273px;"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Sharav%20T%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Tumenjargal Sharav</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"></sup><span style="background-color: white; line-height: 20.399999618530273px;"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Sterry%20W%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Wolfram Sterry</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"></sup><span style="background-color: white; line-height: 20.399999618530273px;"> and </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Walden%20P%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Peter Walden</a><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"></sup><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;">*</sup></b></span></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="line-height: 0px;"><span style="color: #ea9999; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></span></div>
<div>
<span style="line-height: 0px;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="line-height: 0px;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="line-height: 0px;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="line-height: 0px;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="line-height: 0px;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Information on specificities of serological responses against tumor cells in cutaneous lymphoma patients is relatively restricted. To advance the knowledge of serological immune responses against and to assess the scope of tumor antigenicity of cutaneous lymphoma, 1- and 2-dimensional Western blot analyses with sera from patients were combined with proteomics-based protein identification. Testing sera from 87 cutaneous lymphoma patients by 1-dimensional Western blot analysis, 64 cases of seroreactivity against lymphoma cells were found. The positive responses were relatively weak, restricted to few antigens in each case, and heterogeneous. To identify the antigens, proteins of the mycosis fungoides cell line MyLa and primary tumor cells were separated by 2-dimensional gel electrophoresis, Western-blotted and probed with heterogeneous and autologous patient sera. The antigens were identified from silver-stained replica gels by MALDI-TOF mass spectrometry. 14 different antigens were assigned and identified with this proteome-serological approach. Only one, vimentin, had been reported before, the other 13 are new antigens for cutaneous lymphomas.</b></span></span></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Complete Text:</b></span></span></div>
<div>
<span style="background-color: white; font-size: 15.600000381469727px; line-height: 25.200000762939453px;"><span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></span></div>
<div>
<span style="background-color: white; font-size: 15.600000381469727px; line-height: 25.200000762939453px;"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793029/"><span style="font-family: Arial, Helvetica, sans-serif;">NIH - PLOS One</span></a></span></div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-27033338778461667082012-12-26T07:07:00.000-08:002012-12-26T07:07:06.759-08:00Cutaneous T-Cell Lymphoma in Asians<br />
<h1 class="content-title" style="background-color: white; border: 0px; font: inherit; line-height: 1.5; margin: 1em 0px 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Cutaneous T-Cell Lymphoma in Asians</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>July 2012 - Just released through PubMed</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Jang%20MS%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Min Soo Jang</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"> </sup><span style="background-color: white; line-height: 20.399999618530273px;"></span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kang%20DY%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Dong Young Kang</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"> </sup><span style="background-color: white; line-height: 20.399999618530273px;"></span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Park%20JB%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Jong Bin Park</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"> </sup><span style="background-color: white; line-height: 20.399999618530273px;"></span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20ST%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Sang Tae Kim</a><span style="background-color: white; line-height: 20.399999618530273px;">,</span><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"> </sup><span style="background-color: white; line-height: 20.399999618530273px;">and </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Suh%20KS%5Bauth%5D" style="background-color: white; border: 0px; color: #642a8f; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">Kee Suck Suh</a><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"> </sup><sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;">*</sup></b></span></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="color: #b45f06; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="color: #b45f06; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<sup style="background-color: white; border: 0px; font: inherit; line-height: 0; margin: 0px; padding: 0px; position: relative; top: -0.5em; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></sup></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Cutaneous T-cell lymphoma describes a heterogeneous group of neoplasms of skin homing T cells that vary considerably in clinical presentation, histologic appearance, immunophenotype, and prognosis. This paper addresses the cutaneous T-cell lymphoma in Asians with respect to clinical-epidemiologic and histopathological features. Compared with Western countries, Asia usually has higher rates of cutaneous T-cell lymphomas such as extranodal NK/T-cell lymphoma, hydroa vacciniforme-like lymphoma, subcutaneous panniculitis T-cell lymphoma, and adult T-cell leukemia/lymphoma and lower rates of cutaneous B-cell lymphomas. Among many variants of mycosis fungoides, hypopigmented lesions, pityriasis lichenoides-like lesions, and ichthyosiform lesions are more prevalent in Asia than in the West. Adult T-cell leukemia/lymphoma is endemic in southwestern Japan especially in the Kyushu island. The clinicopathologic characteristics of cutaneous lymphoma vary according to geography, and this may be ascribed to genetic and environmental etiologic factors.</b></span></span></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="background-color: white; line-height: 25.200000762939453px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Complete Text with Images</b></span></span></div>
<div>
<span style="background-color: white; font-size: 15.600000381469727px; line-height: 25.200000762939453px;"><span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></span></div>
<div>
<span style="background-color: white; font-size: 15.600000381469727px; line-height: 25.200000762939453px;"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403505/"><span style="font-family: Arial, Helvetica, sans-serif;">NIH - ISRN Dermatology</span></a></span></div>
<div>
<span style="background-color: white; font-family: Georgia, 'Times New Roman', serif; font-size: 15.600000381469727px; line-height: 25.200000762939453px;"><br /></span></div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-19407182705293650642012-12-20T08:20:00.003-08:002012-12-20T08:20:28.300-08:00Cutaneous EBV-positive γδ T-cell lymphoma vs. extranodal NK/T-cell lymphoma: a case report and literature review.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> EBV-positive γδ T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> vs. extranodal NK/T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>: a case report and literature review.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Nov 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yu%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=23240992" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Yu WW</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hsieh%20PP%5BAuthor%5D&cauthor=true&cauthor_uid=23240992" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Hsieh PP</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chuang%20SS%5BAuthor%5D&cauthor=true&cauthor_uid=23240992" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Chuang SS</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div style="line-height: 20.399999618530273px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<b style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: x-large; line-height: 20.399999618530273px;">Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> γδ T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> and </b></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>extranodal natural killer (NK)/T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (ENKTL), nasal type are two distinct <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> entities in the World Health Organization (WHO) classification. We report the case of an aggressive<span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of γδ T-cell origin showing overlapping features of both lymphomas. A 78-year-old female presented with confluent erythematous plaques with ulcerations over her right thigh. Microscopically, section of the skin showed a diffuse dermal and subcutaneous lymphocytic infiltration with tumor necrosis and angioinvasion. The medium- to large-sized tumor cells expressed CD3, CD8, cytotoxic molecules and T-cell receptor (TCR)-γ but not CD4, CD20, CD30, CD56 or βF1. In situ hybridization for Epstein-Barr virus-encoded mRNA (EBER) was diffusely positive. Polymerase chain reaction-based clonality assay showed a clonal TCR-γ chain gene rearrangement. The features compatible with γδ T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> include dermal and subcutaneous involvements, cytotoxic phenotype, expression of TCR-γ, as well as an aggressive course. On the other hand, the diffuse EBER positivity, angioinvasion, tumor necrosis and cytotoxic phenotype may also fit in the diagnosis of an ENKTL of T-cell lineage. We review the literature on EBER-positive γδ T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> and discuss the diagnostic dilemma using the current WHO classification system.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
</div>
<h3 class="keywordsHeading" style="border: 0px; float: left; line-height: 18px; margin: 0.2em 0.5em 0px 0px; outline: 0px; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;">Keywords:</span></h3>
<div class="keywordLists" style="border: 0px; float: left; line-height: 12px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">
<ul class="keywordList" id="abstractKeywords1" style="background-color: transparent; border: 0px; list-style: none; margin: 0px; outline: 0px; overflow: hidden; padding: 0px; vertical-align: baseline; width: 72.3em;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">γδ T-cell;</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">γδ T-cell lymphoma;</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">cutaneous lymphoma;</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">extranodal natural killer,</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">T-cell lymphoma;</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">peripheral T-cell lymphoma;</li>
<li style="background-color: transparent; border: 0px; display: inline; line-height: 1.5em; margin: 0px; outline: 0px; padding: 0px 0.3em 0px 0px; vertical-align: baseline;">Taiwan</li>
</b></span></ul>
</div>
<br />
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://onlinelibrary.wiley.com/doi/10.1111/cup.12066/abstract;jsessionid=AE3FA07F0CDC032B012448A3C9DE8F03.d03t01">Wiley OnLine</a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1tag:blogger.com,1999:blog-5438070892316853836.post-66481230205501254352012-12-20T08:15:00.001-08:002012-12-20T08:15:06.324-08:00Indolent lymphoma of the ear<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Indolent <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of the ear</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="lang" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>[Article in French]</b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Valois%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Valois A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bastien%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Bastien C</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Granel-Broca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Granel-Broca F</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cuny%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cuny JF</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Barbaud%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Barbaud A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Schmutz%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=23237280" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Schmutz JL</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Service de dermatologie, CHU de Brabois, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: audevalois4@yahoo.fr.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<h4 style="border: 0px; float: left; font: inherit; margin: 0px 0.25em 0px 0px; padding: 0px; text-transform: uppercase; vertical-align: baseline;">
<span style="color: #f6b26b; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>INTRODUCTION:</b></span></h4>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>In 2007, Petrella et al. identified a new entity: CD8 T-cell indolent <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of the ear.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<h4 style="border: 0px; float: left; font: inherit; margin: 0px 0.25em 0px 0px; padding: 0px; text-transform: uppercase; vertical-align: baseline;">
<span style="color: #f6b26b; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>CASE REPORT:</b></span></h4>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>A 40-year-old man presented a nodular erythematous and violaceous painless lesion on his right ear that had appeared four months earlier. Excision histology revealed a non-epidermotropic T-cell proliferation infiltrating the entire dermis and subcutis but with sparing of a grenz zone. The monotonous infiltrate was positive for CD8, CD3, CD5 and TIA-1, and negative for CD30, CD4, CD56, ALK and EMA. The Mib1 proliferation index was 20%. Lyme serology and PCR for EBV were negative. Additional examinations showed no extracutaneous involvement.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<h4 style="border: 0px; float: left; font: inherit; margin: 0px 0.25em 0px 0px; padding: 0px; text-transform: uppercase; vertical-align: baseline;">
<span style="color: #f6b26b; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>DISCUSSION:</b></span></h4>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>CD8+ indolent <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> is an entity first described in 2007 and reported in the literature in 15 patients. Lesions are located on the nose or external ear. It comprises a non-epidermotropic proliferation of CD8+ T lymphocytes negative for CD4, CD30, CD56, CD57, granzyme B and perforin. The Mib1 proliferation index is low. This new entity appears neither in the 2005 World Health Organization/European Organization for Research and Treatment of Cancer (WHO/EORTC) classification of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphomas nor in the WHO 2008 Classification of tumours of haematopoietic and lymphoid tissues. Surgical treatment or radiotherapy is sufficient, and unlike aggressive, epidermotropic CD8+ T lymphomas chemotherapy is not required.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000;"><br /></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000;"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23237280">PubMed</a></span></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-22652056886717856472012-12-20T08:09:00.001-08:002012-12-20T08:09:28.611-08:00Integrated Positron-Emission Tomography and Computed Tomography Manifestations of Cutaneous T-Cell Lymphoma<br />
<h1 class="aTitle" style="border: 0px; font: inherit; line-height: 1.3; margin: 0px 0px 5px; padding: 5px 0px 0px; vertical-align: baseline;">
<span id="scm6MainContent_lblArticleTitle" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Integrated Positron-Emission Tomography and Computed Tomography Manifestations of Cutaneous T-Cell Lymphoma</b></span></span></h1>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /><span style="color: #990000;">Dec 2012</span></b></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Research letters</b></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span style="background-color: white; line-height: 22.80000114440918px;">Mycosis fungoides (MF) and Sézary syndrome (SS) represent the most common types of primary cutaneous T-cell lymphomas (CTCLs).</span><span style="background-color: white; line-height: 22.80000114440918px;"> Current guidelines recommend [18F]-fluorodeoxyglucose positron-emission tomography (FDG-PET) plus computed tomography (CT) scan for staging purposes in all patients except in cases of early-stage disease (IA-IB).</span><span style="background-color: white; line-height: 22.80000114440918px;"> However, the application of FDG-PET in CTCL has not been widely documented.</span><span style="background-color: white; line-height: 22.80000114440918px;"> In this study, we retrospectively evaluated the findings of FDG-PET/CT scans in 41 patients with CTCL.</span></b></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="background-color: white; line-height: 22.80000114440918px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></span></div>
<div>
<span style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="background-color: white; line-height: 22.80000114440918px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Complete text</b></span></span></span></div>
<div>
<span style="border: 0px; font-size: 24px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="background-color: white; color: #333333; font-family: Georgia, Cambria, Times, 'Times New Roman', serif; font-size: 15.600000381469727px; line-height: 22.80000114440918px;"><br /></span></span></div>
<div>
<span style="border: 0px; font-size: 24px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="background-color: white; color: #333333; font-family: Georgia, Cambria, Times, 'Times New Roman', serif; font-size: 15.600000381469727px; line-height: 22.80000114440918px;"><a href="http://archderm.jamanetwork.com/article.aspx?articleid=1485960">Archives of Dermatology</a></span></span></div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-74958118097057504892012-12-13T11:51:00.001-08:002012-12-13T11:51:09.932-08:00A Cutaneous Interstitial Granulomatous Dermatitis-Like Eruption Arising in Myelodysplasia With Leukemic Progression.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>A <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> Interstitial Granulomatous Dermatitis-Like Eruption Arising in Myelodysplasia With Leukemic Progression.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cornejo%20KM%5BAuthor%5D&cauthor=true&cauthor_uid=23221468" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cornejo KM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lum%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=23221468" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Lum CA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Izumi%20AK%5BAuthor%5D&cauthor=true&cauthor_uid=23221468" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Izumi AK</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>*Department of Pathology, University of Massachusetts Medical School, Worcester, MA †Department of Pathology ‡Division of Dermatology, Department of Medicine, University of Hawaii, Honolulu, HI.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> manifestations associated with myelodysplastic syndromes (MDS) are uncommon and can occur as specific or nonspecific lesions. Recognizing these <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> manifestations is important as they can precede blood or bone marrow transformation to leukemia. Granulomatous reactions have rarely been described as nonspecific lesions of MDS. These rare cases histologically resembled granuloma annulare, sarcoid, and a generalized dermal interstitial granulomatous dermatitis (IGD) which were not associated with leukemic infiltration. The authors report an interesting case of an IGD-like eruption evolving over the course of MDS with eventual progression to systemic leukemia. IGD is an inflammatory reaction that refers to a varied spectrum of histologic patterns and is associated with a variety of systemic illnesses and hypersensitivity reactions, including <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> and leukemia. In patients with MDS, surveillance for leukemia is a critical component of their follow-up care. Normally, this surveillance occurs through serial peripheral blood smears and bone marrow studies. IGD-like eruptions are a <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> reaction pattern that may serve as an additional clinical indicator of leukemic progression in patients with MDS. Although primarily a reactive pattern, this entity can rarely harbor leukemic blasts.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=9000&issue=00000&article=99324&type=abstract"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>American Journal of Dermatopathology</b></span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-39864550975352929482012-12-05T07:43:00.001-08:002012-12-05T07:43:19.138-08:00Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Nov 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Plaza%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23189966" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Plaza JA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Feldman%20AL%5BAuthor%5D&cauthor=true&cauthor_uid=23189966" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Feldman AL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Magro%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23189966" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Magro C</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatopathology, The Medical College of Wisconsin, Milwaukee, WI, USA.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Lymphomatoid papulosis (LyP) and <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> anaplastic large cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (ALCL) belong to the spectrum of<span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD30+ lymphoproliferative disorders, an indolent form of T-cell lymphoproliferative disease. We reviewed 21 cases of CD30+ lymphoproliferative lesions expressing cytotoxic profile (CD8+). Seven cases of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> ALCL, 2 cases of systemic ALCL involving the skin, and 12 cases of LyP. The cases of LyP were predominated by small lymphocytes exhibiting a prominent epidermotropic pattern consistent with either type B or type D LyP. Four cases showed co-expression of CD56. The ALCL cases included myxoid features, pseudoepitheliomatous change, and an intravascular component. In all cases that were primary in the skin an indolent clinical course was seen while one patient with systemic myxoid ALCL is in remission following systemic multiagent chemotherapy. The paucity of other neutrophils and eosinophils and concomitant granulomatous inflammation were distinctive features in cases of type B and type D LyP. CD30 and CD45 Ro positivity and a clinical course typical of LyP were useful differentiating features from an aggressive cytotoxic CD8+ T cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>. In all cases that were primary in the skin an indolent clinical course was observed. CD30 and CD45 Ro positivity and a clinical course typical of LyP were useful in preventing a misdiagnosis of an aggressive cytotoxic CD8+ T cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://onlinelibrary.wiley.com/doi/10.1111/cup.12047/abstract;jsessionid=7D7F23C81DB4516EB3B09A57A3BC904A.d01t03?systemMessage=Wiley+Online+Library+will+be+disrupted+on+15+December+from+10%3A00-12%3A00+GMT+%2805%3A00-07%3A00+EST%29+for+essential+maintenance"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Wiley OnLine</b></span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-25596219841987883132012-11-25T07:07:00.000-08:002012-11-25T07:07:57.853-08:00The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-size: large;"><b><span style="font-family: arial, helvetica, clean, sans-serif;">T</span><span style="font-family: Arial, Helvetica, sans-serif;">he role of AHI1 and CDKN1C in <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> progression.</span></b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Nov 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Litvinov%20IV%5BAuthor%5D&cauthor=true&cauthor_uid=23171462" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Litvinov IV</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kupper%20TS%5BAuthor%5D&cauthor=true&cauthor_uid=23171462" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kupper TS</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Sasseville%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23171462" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Sasseville D</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Division of Dermatology, McGill University Health Centre, Montréal, QC, Canada.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (CTCL) is the most common <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> of the skin. Recent reports suggest that AHI1 is overexpressed in a subset of CTCL-derived cell lines, where it downregulates the expression of CDKN1C tumor suppressor gene. In the current work, we test the expression of these genes in 60 patients with Mycosis Fungoides and Sezary Syndrome by RT-PCR and correlate our findings with 6 years of clinical follow-up. These findings reveal that AHI1 and CDKN1C exhibit opposite expression patterns, where AHI1 is expressed in poor and intermediate prognosis patients, while CDKN1C is expressed in favourable prognosis patients. Kaplan-Meier analysis documents that downregulation of CDKN1C is associated with poor disease outcome in patients with CTCL, while upregulation of AHI1 shows a weak association with aggressive disease course.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://onlinelibrary.wiley.com/doi/10.1111/exd.12039/abstract"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Wiley Online</b></span></a></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-12690633609716675772012-11-25T07:04:00.003-08:002012-11-25T07:04:40.096-08:00The role of molecular analysis in cutaneous lymphomas.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>The role of molecular analysis in <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphomas.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Deonizio%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=23174493" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Deonizio JM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Guitart%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23174493" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Guitart J</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, Northwestern University, Chicago, IL.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>The purpose of this review is to summarize the most important molecular techniques for the diagnosis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous </span>lymphomas. When making a diagnosis, we are looking for the solid clinicopathological correlation. Molecular analysis includes immunophenotyping and clonality analysis, and is important for 2 principal reasons: (1) to confirm the diagnosis in cases where the clinical and/or pathological presentations are nondiagnostic, and (2) to further characterize the nature of the <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>. More specifically, we are trying to discern whether the <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> is primarily <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> or systemic with secondary skin involvement, and we are also attempting to subclassify the tumor. Recently, many techniques have provided a more accurate diagnosis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphomas and some prognostic implications, including polymerase chain reaction, fluorescence in situ hybridization, and flow cytometry. Fluorescence in situ hybridization is not routinely used in the diagnosis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>, but many studies have shown potential future applications in various areas. Other techniques, such as comparative genomic hybridization, are still confined to the research arena, but have added some insight into the molecular pathogenesis of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23174493"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>PubMed</b></span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-54256708347519819452012-11-18T06:13:00.002-08:002012-11-18T06:13:39.738-08:00Radiographically negative, asymptomatic, sentinel lymph node positive cutaneous T-cell lymphoma in a 3-year-old male: a case report.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Radiographically negative, asymptomatic, sentinel lymph node positive cutaneous T-cell lymphoma in a 3-year-old male: a case report.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<br />
<br />
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Carson%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23150841" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Carson J</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bedrnicek%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23150841" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Bedrnicek J</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Abdessalam%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23150841" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Abdessalam S</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of General Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>We present a case of a 3-year-old male originally diagnosed with a CD30+ anaplastic cutaneous T-cell lymphoma with no evidence of systemic disease after CT scan, PET scan, and bone marrow aspiration. Sentinel lymph node biopsy (SLNB) was performed as an additional step in the workup and showed microscopic disease. Current management/recommendations for cutaneous T-cell lymphoma do not include SLNB. Medical and surgical management of cutaneous malignancies is dramatically different for local versus advanced disease. Therefore adequate evaluation is necessary to properly stage patients for specific treatment. Such distinction in extent of disease suggests more extensive therapy including locoregional radiation and systemic chemotherapy versus local excision only. Two international case reports have described SLNB in cutaneous T-cell lymphoma with one demonstrating evidence of node positive microscopic disease despite a negative metastatic disease workup. This case is being presented as a novel case in a child with implications including lymphoscintigraphy and SLNB as a routine procedure for evaluation and staging of cutaneous T-cell lymphoma if the patient does not demonstrate evidence of metastatic disease on routine workup.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488386/"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>NIH</b></span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-11833198748936312152012-11-18T06:11:00.004-08:002012-11-18T06:11:38.838-08:00Advanced/aggressive CTCL: improving the efficacy of treatment.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Advanced/aggressive CTCL: improving the efficacy of treatment.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Zinzani%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=23149702" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Zinzani PL</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>"L. e A. Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Treatment regimens of patients with cutaneous T-cell lymphoma (CTCL) vary widely based on clinician preference and patient tolerance. Skin directed therapies are recommended for patients with early stage IA and IB MF, with combinations used in refractory cases. While no regimen has been proven to prolong survival in advanced stages, immunomodulatory regimens should be used initially to reduce the need for cytotoxic therapies. In more advanced stages of disease, treatment efforts should strive for palliation and improvement of quality of life. With many new therapies and strategies on the horizon, the future looks promising for CTCL patients.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed/23149702">PubMed</a>C</b></span></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-45537960748160440752012-11-18T06:08:00.000-08:002012-11-18T06:09:05.797-08:00Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas.<br />
<h1 style="background-color: white; border: 0px; font: inherit; line-height: 1.125em; margin: 0.375em 0px; padding: 0px; vertical-align: baseline;">
<span style="color: orange; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> lymphomas.</b></span></h1>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div>
<span style="color: #660000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Dec 2012</b></span></div>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div class="auths" style="background-color: white; border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kempf%20W%5BAuthor%5D&cauthor=true&cauthor_uid=23149701" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kempf W</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Rozati%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23149701" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Rozati S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kerl%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23149701" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Kerl K</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=French%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=23149701" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">French LE</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Dummer%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23149701" style="border: 0px; color: #660066; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Dummer R</a>.</b></span></div>
<div class="aff" style="background-color: white; border: 0px; font: inherit; line-height: 1.0915em; margin: 0px; padding: 0px; vertical-align: baseline;">
<h3 class="label" style="border: 0px; color: #724128; font: inherit; height: 1px; left: -10000px; line-height: 1.2857; margin: 1.2856em 0px 0.6428em; overflow: hidden; padding: 0px; position: absolute; top: auto; vertical-align: baseline; width: 1px;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Source</b></span></h3>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; margin-top: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #660000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Department of Dermatology, University Hospital Zürich, Zürich, Switzerland - werner.kempf@access.unizh.ch.</b></span></div>
</div>
<div class="abstr" style="background-color: white; border: 0px; font: inherit; line-height: 20.399999618530273px; margin: 1.2em auto auto; padding: 0px; vertical-align: baseline;">
<h3 style="border: 0px; color: #985735; font: inherit; line-height: 1.2857; margin: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Abstract</b></span></h3>
<div>
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #660000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">Cutaneous</span> peripheral T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>, unspecified/not otherwise specified (PTL NOS) represents a phenotypically and prognostically heterogenous group of <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> T-cell lymphomas (CTCL) that do not fit into any of well defined defined CTCL subtypes. In the WHO-EORTC classification as well as the WHO classification, three entities have been delineated as provisional rare subtypes of PTL based on their characteristic clinico-pathological, immunophenotypic and prognostic features and have been separated out from PTL, NOS: Primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD4-positive small/medium T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span>(CD4+ SMTL), primary <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> CD8-positive aggressive epidermotropic T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (CD8+ AECTCL), and primary<span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">cutaneous</span> gamma/delta T-cell <span class="highlight" style="border: 0px; font: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">lymphoma</span> (CGD-TCL). CD4+ SMTL manifests in most patients with a solitary nodule in the head and neck area and nodular infiltrates of CD4+ small to medium-sized lymphocytes with nuclear pleomorphism. The prognosis of this lymphoproliferation is excellent in patients with a solitary lesion, but may be impaired in patients with multifocal disease. Rapidly evolving erosive or necrotic plaques and nodules with an epidermotropic infiltrate of CD8+ atypical lymphocytes are the hallmark of CD8+ AECTCL, which exhibits a poor prognosis. CGD-TCL displays a broad spectrum of clinical and histological manifestations with expression of the T-cell receptor gamma/delta chain as the common denominator and diagnostic marker. As most of other forms of PTL, CGD-TCL carries a poor prognosis. Despite the rarity of PTL NOS, clinicians as well as dermatopathologists and pathologists should be familiar with these rare CTC, especially since most of these lymphomas exhibit an unfavourable prognosis. Immediate intense treatment with multiagent chemotherapy and hematopoietic stem cell transplantation is indicated in patients with PTL NOS. This review focuses on the clinicopathological aspects, the diagnostic criteria and the classification of the rare subtypes of PTL and PTL NOS.</b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></div>
<div style="border: 0px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23149701"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>PubMed</b></span></a></div>
<div style="border: 0px; font-size: 15.600000381469727px; font: inherit; margin-bottom: 0.5em; padding: 0px; vertical-align: baseline;">
<br /></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com0tag:blogger.com,1999:blog-5438070892316853836.post-22446181121755961982012-11-13T07:54:00.002-08:002012-11-13T07:54:40.042-08:00MDx/CDx Focus: Phase III Adcetris Trial in Hodgkin Lymphoma; FDA Priority Review for Roche's T-DM1<br />
<h2 class="title" style="background-color: white; border: 0px; font-family: Arial, Helvetica, sans-serif; font-weight: normal; line-height: 21.600000381469727px; margin: 0px 0px 0.35em; padding: 0px; vertical-align: baseline;">
<span style="color: orange;">MDx/CDx Focus: Phase III Adcetris Trial in Hodgkin Lymphoma; FDA Priority Review for Roche's T-DM1</span></h2>
<div>
<span style="color: orange;"><br /></span></div>
<div>
<span style="background-color: white; line-height: 20.260000228881836px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>November 07, 2012</b></span></span></div>
<div>
<span style="background-color: white; line-height: 20.260000228881836px;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b><br /></b></span></span></div>
<div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<em style="border: 0px; margin: 0px; padding: 0px; vertical-align: baseline;"><span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Millennium, Seattle Genetics Launch Phase III Adcetris Trial in Hodgkin Lymphoma</b></span></em></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Millennium and Seattle Genetics earlier this month initiated a Phase III trial to investigate the efficacy and safety of Adcetris, a drug being developed for the treatment of advanced Hodgkin lymphoma.</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Adcetris targets the cell membrane protein CD30, which is expressed in Hodgkin lymphoma. The trial, being conducted under a special protocol agreement with the US Food and Drug Administration, will study Adcetris (brentuximab vedotin) in combination with chemotherapy as a first-line treatment for previously untreated Hodgkin lymphoma patients.</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>“This is a key step in our efforts to explore the potential of this targeted therapy as part of a front-line treatment regimen,” Karen Ferrante, chief medical officer of Millennium, a subsidiary of Takeda Pharmaceuticals' oncology division, said in a statement.</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>This trial is part of Millennium and Seattle's ongoing program to identify patient populations with CD30-expressing malignancies that might benefit from Adcetris treatment.</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Earlier this year, Millennium and Seattle Genetics launched a Phase III study evaluating Adcetris in previously treated patients with CD30-expressing cutaneous T-cell lymphoma. In this study, the partners are also evaluating a companion test to identify patients with CD30-expressing malignancies. Millennium and Seattle Genetics have inked a deal with Ventana Medical Systems to develop the molecular companion diagnostic test accompanying Adcetris (<a href="http://www.genomeweb.com/mdx/mdxcdx-focus-assurerx-launches-adhd-pgx-test-adcetris-phase-iii-study-cd-30-lymp" style="border: 0px; font-style: inherit; margin: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;"><em style="border: 0px; margin: 0px; padding: 0px; vertical-align: baseline;">PGx Reporter 5/9/2012</em></a>).</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Seattle Genetics Chief Medical Officer Thomas Reynolds noted in a statement that there is an unmet medical need for new treatments for Hodgkin lymphoma. This Phase III trial might lead to the development of a new front-line treatment for Hodgkin lymphoma patients, but it also may yield data that the companies can submit to the FDA to garner accelerated approval for Adcetris in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma patients.</b></span></div>
<div style="background-color: white; border: 0px; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<span style="color: #990000; font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>The randomized, open-label study will compare Adcetris plus combination chemotherapy (adriamycin, vinblastine, dacarbazine) versus just chemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) in more than 1,000 patients with advanced, classical Hodgkin lymphoma. Researchers will investigate whether the Adcetris plus chemo regimen improves progression-free survival in patients compared to only chemo based on the <a href="http://jco.ascopubs.org/content/25/5/579.full.pdf" style="border: 0px; font-style: inherit; margin: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;" target="_blank">Revised Response Criteria</a> for malignant lymphoma. Other endpoints that will be studied include overall survival, complete remission, and safety.</b></span></div>
<div style="background-color: white; border: 0px; color: #222222; line-height: 21.600000381469727px; margin-bottom: 1.5em; padding: 0px; vertical-align: baseline;">
<a href="http://www.genomeweb.com/clinical-genomics/mdxcdx-focus-phase-iii-adcetris-trial-hodgkin-lymphoma-fda-priority-review-roche"><span style="font-family: Arial, Helvetica, sans-serif; font-size: large;"><b>Pharmacogenomics Reporter</b></span></a></div>
</div>
Pat O'Connorhttp://www.blogger.com/profile/13638920419420663623noreply@blogger.com1